Esaxerenone shows promise for hypertensive patients with primary aldosteronism
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor (MR) blocker, has good safety and efficacy profiles in patients with hypertension and primary aldosteronism, a recent Japan study has found.